CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,622,337 | -23.4% | 872,931 | -5.3% | 0.04% | -21.6% |
| Q2 2023 | $51,741,768 | +35.0% | 921,656 | +8.8% | 0.05% | +30.8% |
| Q1 2023 | $38,322,158 | +10.5% | 847,273 | -0.7% | 0.04% | +5.4% |
| Q4 2022 | $34,669,939 | -36.9% | 852,889 | +1.4% | 0.04% | -39.3% |
| Q3 2022 | $54,940,000 | -2.1% | 840,706 | -9.0% | 0.06% | +5.2% |
| Q2 2022 | $56,131,000 | -12.1% | 923,671 | -9.3% | 0.06% | +5.5% |
| Q1 2022 | $63,888,000 | -26.2% | 1,017,827 | -10.9% | 0.06% | +19.6% |
| Q4 2021 | $86,590,000 | -23.5% | 1,142,652 | +13.0% | 0.05% | -25.8% |
| Q3 2021 | $113,189,000 | -34.2% | 1,011,241 | -4.8% | 0.06% | -31.9% |
| Q2 2021 | $171,930,000 | +34.0% | 1,062,014 | +0.9% | 0.09% | +40.0% |
| Q1 2021 | $128,310,000 | +1.8% | 1,053,010 | +28.0% | 0.06% | +6.6% |
| Q4 2020 | $126,001,000 | +111.3% | 822,944 | +15.4% | 0.06% | +69.4% |
| Q3 2020 | $59,642,000 | +11.8% | 713,086 | -1.8% | 0.04% | -5.3% |
| Q2 2020 | $53,347,000 | +47.7% | 725,910 | -14.8% | 0.04% | +22.6% |
| Q1 2020 | $36,127,000 | -17.8% | 851,867 | +18.1% | 0.03% | -3.1% |
| Q4 2019 | $43,931,000 | +46.8% | 721,312 | -1.2% | 0.03% | +28.0% |
| Q3 2019 | $29,916,000 | -20.5% | 729,828 | -8.6% | 0.02% | -24.2% |
| Q2 2019 | $37,608,000 | +18.2% | 798,472 | -10.3% | 0.03% | +13.8% |
| Q1 2019 | $31,810,000 | +43.7% | 890,564 | +14.9% | 0.03% | +26.1% |
| Q4 2018 | $22,138,000 | -16.3% | 774,873 | +30.0% | 0.02% | -4.2% |
| Q3 2018 | $26,435,000 | +17.8% | 596,052 | +56.0% | 0.02% | +9.1% |
| Q2 2018 | $22,450,000 | +9.9% | 382,064 | -14.5% | 0.02% | +15.8% |
| Q1 2018 | $20,435,000 | +96.5% | 447,048 | +0.9% | 0.02% | +111.1% |
| Q4 2017 | $10,398,000 | +626.6% | 442,845 | +453.2% | 0.01% | +800.0% |
| Q3 2017 | $1,431,000 | +11.6% | 80,048 | +0.1% | 0.00% | 0.0% |
| Q2 2017 | $1,282,000 | -26.4% | 80,000 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $1,742,000 | – | 80,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |